Source: Sackmann-Sala L. et al., Growth Hormone & IGF Research, 2009, 10.1016/j.ghir.2009.02.004
To evaluate the effect of CJC-1295 – a long-acting analog of Growth Hormone Releasing Hormone (GHRH) – on the activity of the GH/IGF-1 axis and its associated biomarkers in humans.
CJC-1295 is a modified GHRH peptide with an extended plasma half-life that stimulates the endogenous secretion of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). The study aims to determine whether the peptide provides sustained activation of the GH/IGF-1 axis and whether serum biomarkers of the hormonal response can be identified.
Type: clinical, experimental study in humans
Participants: healthy volunteers (men and women)
Interventions:
Single subcutaneous injection of CJC-1295
Control group without treatment
Doses: 30–60 µg/kg (single administration)
Follow-up duration: up to 14 days after injection
Measured parameters:
Serum GH and IGF-1 levels
Proteomic changes (plasma biomarkers)
GH/IGF-1 activation signatures
Activation of the GH / IGF-1 Axis
CJC-1295 induces a significant and sustained increase in GH and IGF-1.
GH peaks are observed within 2–6 hours after injection, while IGF-1 remains above baseline levels for up to 10–14 days.
The increase is dose-dependent and shows a prolonged effect compared to standard GHRH analogs.
Proteomic Changes
Serum proteins whose expression changes after CJC-1295 administration have been identified.
Biomarkers of GH/IGF-1 activity suitable for monitoring the therapeutic effect have been identified.
Biochemical Parameters
No clinically significant changes in glucose, insulin, or liver enzymes were observed.
The hormonal response is physiological and controlled.
Tolerability
CJC-1295 is very well tolerated.
No serious side effects or signs of systemic toxicity were observed.
CJC-1295 activates the GH/IGF-1 axis in a sustained and dose-dependent manner.
It has been shown to increase GH and IGF-1 for weeks after a single administration.
It provides a prolonged effect and less frequent dosing compared to conventional GHRH peptides.
Suitable for research purposes related to hormonal activation and anabolic processes.
Small number of participants.
Short follow-up period – long-term data are lacking.
Patients with GH deficiency or metabolic disorders were not included.
CJC-1295 is a promising long-acting GHRH analog.
Suitable for scientific research on the GH/IGF-1 axis, GH deficiency models, and studies of muscle regeneration.
Can be used under controlled laboratory conditions for pharmacodynamic studies.